Truist analyst David MacDonald lowered the firm’s price target on Pacs Group (PACS) to $40 from $48 and keeps a Buy rating on the shares. Pacs Group is well-positioned into 2026 following the November conclusion of the Audit Committee investigation with committee recommendations having been or being implemented, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PACS:
- PACS Group stockholders endorse directors, auditor and pay
- Pacs Group resumed with a Buy at UBS
- Pacs Group reinstated with an Overweight at JPMorgan
- Buy Recommendation for PACS Group Inc.: Strategic Expansion in Skilled Nursing Facilities with Strong Growth Potential
- Pacs Group price target raised to $40 from $32 at Truist